Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (9507)	11/18/2003 2:34:02 AM
From: Miljenko Zuanic	Respond to of 52153

<<Wasn't this simply a result of the patients selected for the trial. They had worse vision (as bad as 20/320) and larger lesion sizes (closer to blindness endpoint). Thus whether or not they were treated it was more difficult for them to lose another 3 lines of vision.>> Again, it is hard to say. This is 12 months trial, so regardless what advance stage they are loosing another 3 lines is just function of time. I do not know are there specific stages but once disease progressed, it progressed more rapidly at end, imo. In this case one should not expect many stable disease, and only few placebo responders. Maybe I am wrong. Miljenko